Mesoblast/MESO

$5.37

-6.28%
-
1D1W1MYTD1YMAX

About Mesoblast

Mesoblast Limited is an Australia-based is developing a range of late-stage product candidates derived from its proprietary mesenchymal lineage cell therapy technology platforms. The Company’s Remestemcel-L is mesenchymal lineage stromal cell product platform and is in late-stage development for treatment of systemic inflammatory diseases, including Pediatric steroid refractory acute Graft versus Host Disease (SR-aGVHD), acute respiratory distress syndrome (ARDS) and Biologic refractory inflammatory bowel disease. Its Rexlemestrocel-L is mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of advanced chronic heart failure (CHF) and chronic low back pain (CLBP) due to degenerative disc disease. Two products are commercialized in Japan and Europe by the Company’s licensees, and it has a commercial partnership in Europe and China for certain Phase III assets.

Ticker

MESO

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Silviu Itescu

Employees

83

Headquarters

Melbourne, Australia

Mesoblast Metrics

BasicAdvanced
$641.19M
Market cap
-
P/E ratio
-$1.44
EPS
3.57
Beta
-
Dividend rate
$641.19M
3.57012
$10.24
$1.61
2.22M
2.715
21.743
23.981
-3.01%
-10.92%
-14.49%
-11.67%
85.881
0.536
-38.44%

What the Analysts think about Mesoblast

Analyst Ratings

Majority rating from 2 analysts.
Buy

Price Targets

Average projection from 1 analyst.
48.98% upside
High $8.00
Low $8.00
$5.37
Current price
$8.00
Average price target

Mesoblast Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-984.84% profit margin
QuarterlyAnnual
Q2 24
QoQ growth
Revenue
$3.3M
57.14%
Net income
$-32.5M
48.4%
Profit margin
-984.84%
-5.56%

Mesoblast Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 9.68%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.24
-$0.30
-$0.26
-$0.28
-
Expected
-$0.33
-$0.28
-$0.33
-$0.31
-$0.32
Surprise
-26.53%
7.14%
-21.69%
-9.68%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
ADR

Upcoming events

FAQs

What’s the current market cap for Mesoblast stock?

Mesoblast (MESO) has a market cap of $641.19M as of April 14, 2024.

What is the P/E ratio for Mesoblast stock?

The price to earnings (P/E) ratio for Mesoblast (MESO) stock is 0 as of April 14, 2024.

Does Mesoblast stock pay dividends?

No, Mesoblast (MESO) stock does not pay dividends to its shareholders as of April 14, 2024.

When is the next Mesoblast dividend payment date?

Mesoblast (MESO) stock does not pay dividends to its shareholders.

What is the beta indicator for Mesoblast?

Mesoblast (MESO) has a beta rating of 3.57. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Mesoblast stock price target?

The target price for Mesoblast (MESO) stock is $8, which is 48.98% above the current price of $5.37. This is an average based on projections from 1 analyst, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Mesoblast stock

Buy or sell Mesoblast stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing